Indications
lead translational priority-epigenetic bone regeneration
Development Opportunities
•Known/prototype compounds
Commercially available candidates with preclinical support
Example: GSK126, tazemetostat
Commercially available candidates with preclinical support
Example: GSK126, tazemetostat
•Extensor lead compounds
First in class nuclear bone stimulators (EBI-700 series)
Prior SBIR/R43-supported development foundation
First in class nuclear bone stimulators (EBI-700 series)
Prior SBIR/R43-supported development foundation
•Novel Extensor-Cayman collaboration compounds
New chemical matter with stronger material IP potential
Current translational priority
New chemical matter with stronger material IP potential
Current translational priority
SECONDARY AREAS OF INVESTIGATION
Osteoarthritis
Novel approaches to degeneration and joint preservation.
Fibrosis
Targeting pathological soft tissue remodeling and fibrosis.
Inflammatory Musculoskeletal Disease
Exploring pathways involved in chronic musculoskeletal inflammation and tissue dysfunction.